Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyAvalon Lyme Disease Testing Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedAvalon Healthcare SolutionsPolicy AHS - G2143

    Lyme Disease Testing

    Customize your policy alerts

    Sign up for avalon_healthcare_solutions Policy AHS - G2143 alerts

    Get alerted when Policy AHS - G2143 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of laboratory testing for suspected Lyme disease, including indications for two-tier serologic testing and circumstances in which testing is not covered.

    Policy Summary
    PayerAvalon Healthcare Solutions
    PolicyLyme Disease Testing
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateFebruary 1, 2026
    Next Review DateN/A
    Key ActionUse an initial EIA/ELISA or IFA as the first tier, followed by second-tier testing only when the result is positive, equivocal, or indeterminate.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    A new laboratory code, 0316U, was added to the policy.

    The policy background, guidelines, recommendations, and scientific references were updated through successive reviews.

    The policy was edited for clarity and consistency, and its name was changed from a prior Lyme disease title.

    2-tierSerologic testing strategy
    4 weeksIgM usefulness after symptom onset
    1New laboratory code added
    NoneCoverage criteria change

    Covered and Excluded Testing Criteria

    Symptomatic Patient With Endemic-Region Exposure

    Covered when the individual has symptoms of Lyme disease and plausible geographic exposure.

    ALL of the following

    • Symptoms consistent with Lyme disease.
    • History of travel to or residence in a region endemic for Lyme disease, with or without a known tick bite.
    • Serologic testing uses a two-tier strategy: a sensitive enzyme immunoassay (EIA) or immunofluorescence assay (IFA), followed by a western immunoblot or an FDA-cleared second EIA assay.

    Cardiac or Neurologic Presentation With Endemic-Region Exposure

    Covered when there is plausible endemic-region exposure and a compatible cardiac or neurologic presentation.

    ALL of the following

    • History of travel to or residence in a region endemic for Lyme disease.
    • ONE or more of the following clinical presentations

      • Acute myocarditis or pericarditis of unknown cause.
      • Meningitis, encephalitis, or myelitis.
      • Painful radiculoneuritis.
      • Mononeuropathy multiplex, including confluent mononeuropathy multiplex.
      • Acute cranial neuropathy, particularly cranial nerve VII or VIII and less commonly III, V, VI, or other cranial nerves.

    Standard and Modified Two-Tier Serologic Testing

    Use the standard or modified two-tier serologic algorithm for covered Lyme disease testing.

    ALL of the following steps

    • Perform a first-tier EIA or IFA to detect antibodies to Borrelia burgdorferi.
    • If the first-tier result is negative, consider the patient seronegative and do not perform further testing on that specimen.
    • If the first-tier result is positive, equivocal, or indeterminate, perform second-tier testing.
    • ONE of the following second-tier options

      • Standard two-tier testing with a western immunoblot.
      • Modified two-tier testing with an EIA specifically cleared by the FDA for use as the second-tier confirmatory test.

    Clinical Indications for Testing

    Testing is appropriate when compatible clinical findings are accompanied by plausible epidemiologic exposure and is not intended as nonspecific screening.

    ALL of the following

    • Clinical findings are compatible with Lyme disease, including an acute neurologic syndrome, acute myocarditis or pericarditis of unknown cause, or compatible Lyme arthritis manifestations such as brief attacks of arthralgia or intermittent or persistent arthritis in one or a few large joints, especially the knee.
    • There is epidemiologically plausible exposure to ticks infected with B. burgdorferi, including residence in or travel to an endemic area.

    Presentation-Specific Test Selection

    Select testing based on the clinical presentation and use validated, FDA-cleared or guideline-supported methods.

    ONE of the following presentation-specific pathways

    • ALL of the following

      • Typical erythema migrans lesion in a patient with plausible tick exposure.
      • Make a clinical diagnosis rather than laboratory testing.
    • ALL of the following

      • A skin lesion suggestive of but atypical for erythema migrans.
      • Perform antibody testing on an acute-phase serum sample; if negative, obtain a convalescent-phase serum sample at least 2–3 weeks later.

    COVERAGE CRITERIA — DOES NOT MEET: Serologic testing for individuals with an erythema migrans rash. Patients with a rash clinically consistent with erythema migrans who live in or recently traveled to an endemic area should be treated clinically for Lyme disease.

    Serologic testing to screen asymptomatic patients living in endemic areas or following an Ixodes tick bite does not meet coverage criteria.

    Serologic testing for nonspecific symptoms alone, including fatigue, myalgias, arthralgias, diffuse arthralgias, myalgias, or fibromyalgia, does not meet coverage criteria.

    Routine testing does not meet coverage criteria for typical amyotrophic lateral sclerosis, relapsing-remitting multiple sclerosis, Parkinson's disease, dementia or cognitive decline, new-onset seizures, psychiatric illness, or developmental, behavioral, or psychiatric disorders in children.

    Routine testing does not meet coverage criteria for chronic cardiomyopathy of unknown cause, nonspecific brain white-matter MRI abnormalities without other clinical or epidemiologic support, or neurologic syndromes not listed above without other clinical or epidemiologic support.

    COVERAGE CRITERIA — DOES NOT MEET: Detection of Borrelia burgdorferi by nucleic acid identification techniques, including direct or amplified probe methods, does not meet coverage criteria.

    Testing an individual removed tick for B. burgdorferi does not meet coverage criteria. Tick species identification may be submitted for guidance, but testing the tick for B. burgdorferi does not reliably predict clinical infection.

    COVERAGE CRITERIA — DOES NOT MEET: All other testing for Borrelia burgdorferi not specifically described in the covered criteria does not meet coverage criteria.

    COVERAGE CRITERIA — DOES NOT MEET: Do not routinely test asymptomatic patients after a tick bite or other potential exposure. Testing removed ticks does not predict whether the individual will develop infection.

    Patients with typical erythema migrans should receive a clinical diagnosis and treatment rather than laboratory testing. For lesions atypical for erythema migrans, use acute-phase antibody testing followed by convalescent-phase testing if initially negative; use antibody testing rather than currently available direct detection methods such as PCR or culture of blood or skin.

    COVERAGE CRITERIA — DOES NOT MEET: Do not order a western immunoblot as the initial test, when the first-tier EIA or IFA is negative, or without a preceding EIA or IFA, because specificity is diminished when immunoblot testing is performed alone.

    An IgM immunoblot is useful only during the first 4 weeks after symptom onset. Disregard, or do not order when possible, a positive IgM result in patients with symptoms lasting longer than 4 weeks or with symptoms consistent with late Lyme disease; false-positive IgM results are common in these settings.

    COVERAGE CRITERIA — DOES NOT MEET: Urine tests for B. burgdorferi, CD57 assays, novel culture techniques, and antibody panels that differ from standardized two-tier testing are not appropriate diagnostic tests and do not meet coverage criteria. These tests are not FDA cleared or lack sufficient validity and specificity.

    COVERAGE CRITERIA — DOES NOT MEET: Other Lyme disease testing without sufficient published scientific support confirming that the test is required and beneficial for diagnosis or treatment does not meet coverage criteria.

    COVERAGE CRITERIA — DOES NOT MEET: Repeat antibody testing in individuals who previously tested positive for Lyme disease is not medically necessary. Antibodies may persist for many years after successful treatment and should not be repeated to document cure or assess treatment response.

    COVERAGE CRITERIA — DOES NOT MEET: Routine blood PCR is not recommended because its role is not well established and results are usually negative in early and late disease.

    Routine CSF PCR or culture does not meet coverage criteria; yield of CSF PCR in neuroborreliosis is too low to exclude the diagnosis. When CSF testing is performed for suspected central nervous system neuroborreliosis, use simultaneous CSF and serum antibody testing with a validated CSF:serum antibody index, not CSF serology alone.

    For possible Lyme arthritis, use serum antibody testing rather than blood or synovial fluid/tissue PCR or culture. In a seropositive patient requiring additional diagnostic specificity, synovial fluid or tissue PCR may be used rather than Borrelia culture.

    Procedure Codes and Testing Timing

    Applicable CPT/HCPCS Procedure CodesCPT
    86617Antibody; Borrelia burgdorferi (Lyme disease) confirmatory test (eg, Western Blot or immunoblot).
    86618Borrelia burgdorferi antibody detection.
    87475Infectious agent detection by nucleic acid (DNA or RNA); Borrelia burgdorferi, direct probe technique.
    87476Infectious agent detection by nucleic acid (DNA or RNA); Borrelia burgdorferi, amplified probe technique.
    0041UProprietary test: Lyme ImmunoBlot IgM; laboratory/manufacturer: IGeneX Inc.
    Added codeCPT
    0316UNew code added; code description is not provided in this window.
    IgM immunoblot usefulness
    TestIgM immunoblot
    Useful periodFirst 4 weeks after symptom onset
    After 4 weeksDisregard or avoid IgM immunoblot results because false-positive results are common
    Convalescent serum collection
    Sample typeConvalescent-phase serum
    Collection timingAt least 23 weeks after the acute-phase serum sample
    Use

    Ordering, Documentation, and Denial-Risk Guidance

    Documentation Required

    Use the CDC Two-Step Serologic Process

    Use the CDC-recommended two-step serologic process for blood testing. Begin with an EIA (enzyme immunoassay) or, less commonly, an IFA; if the first-tier result is negative, do not perform additional testing on that specimen. If positive or equivocal, proceed to second-tier testing with an immunoblot or an FDA-cleared EIA-based alternative.

    • Results are considered positive only when both tiers are positive.
    • Both steps may be performed using the same blood sample.
    • Use FDA-cleared assays; alternatives to one or both steps must be cleared for this purpose.
    Billing Rule

    Complete First-Tier Testing Before Confirmation

    Policy Background

    Lyme disease is a multisystem inflammatory infection caused by Borrelia species and transmitted primarily through infected Ixodes ticks. Early infection may produce erythema migrans and flu-like symptoms; disseminated disease may involve the heart, joints, peripheral or central nervous system, and cranial nerves. Diagnosis depends on compatible clinical findings and plausible geographic or epidemiologic exposure, with laboratory testing used when indicated. Typical erythema migrans is diagnosed clinically, while serologic testing is preferred for compatible neurologic, cardiac, or articular presentations.

    Terms and Abbreviations

    EIA
    AbbreviationEIA
    Full termEnzyme immunoassay
    Policy useInitial assay in the two-tier serologic testing process
    IFA
    AbbreviationIFA
    Full termImmunofluorescence assay
    Policy useInitial assay that may be used in the two-tier serologic testing process

    Indications Supporting Coverage

    Symptoms of Lyme Disease With Endemic-Region Travel

    Covered when the individual has symptoms of Lyme disease and a history of travel to a Lyme-endemic region, with or without a known tick bite.

    Symptomatic endemic-region presentation

    • Exposure history: History of travel to a region endemic for Lyme disease, with or without a known tick bite.
    • Testing method: Use a two-tier serologic testing strategy consisting of a sensitive EIA or immunofluorescence assay followed by a western immunoblot assay or an FDA-cleared second EIA assay.Two tiers

    Endemic-Region Travel Plus Acute Cardiac or Neurologic Presentation

    Covered when endemic-region travel is accompanied by at least one qualifying acute cardiac or neurologic presentation.

    Repeat Testing and Frequency Restrictions

    Lyme disease serologic testing
    TestLyme disease serologic testing
    Prior resultPrevious positive Lyme disease test
    Coverage ruleRepeat serologic testing is not covered
    Lyme antibody testing
    TestLyme antibody testing
    Repeat testingDo not repeat antibody testing after antibodies have developed
    Treatment monitoringDo not use antibody testing to assess treatment success or confirm eradication

    Required Testing Sequence

    Billing Rule

    Ordering requirement for Lyme serology

    The initial Lyme serology must be an EIA/ELISA or IFA. Order reflex or follow-up second-tier testing only when the first-tier result is positive, equivocal, or indeterminate.

    Testing Excluded From Coverage

    The following testing is not covered: Borrelia burgdorferi nucleic acid identification by direct or amplified probe; testing an individual or removed Ixodes tick; urine B. burgdorferi testing, CD57 assays, novel culture techniques, and nonstandard antibody panels; routine blood PCR, CSF PCR, and culture; and other testing not specifically described as covered. Testing asymptomatic patients solely after an Ixodes tick bite and testing typical erythema migrans lesions are also not covered.

    Policy Summary
    PayerAvalon Healthcare Solutions
    PolicyLyme Disease Testing
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateFebruary 1, 2026
    Next Review DateN/A
    Key ActionUse an initial EIA/ELISA or IFA as the first tier, followed by second-tier testing only when the result is positive, equivocal, or indeterminate.
    SourceLink
    On This Page
    Covered and Excluded Testing CriteriaProcedure Codes and Testing TimingOrdering, Documentation, and Denial-Risk GuidancePolicy BackgroundTerms and AbbreviationsIndications Supporting CoverageRepeat Testing and Frequency RestrictionsRequired Testing SequenceTesting Excluded From Coverage
    Evidence of spinal cord or, rarely, brain inflammation, particularly when associated with painful radiculitis involving related spinal cord segments.
  1. Serologic testing uses a two-tier strategy: a sensitive EIA or IFA followed by a western immunoblot or an FDA-cleared second EIA assay.
  2. ALL of the following

    • Possible Lyme neuroborreliosis involving the peripheral or central nervous system.
    • Use serum antibody testing rather than PCR or culture of CSF or serum.
    • If CSF testing is performed for suspected central nervous system neuroborreliosis, obtain simultaneous CSF and serum for a validated CSF:serum antibody index; do not use CSF serology without the index.
  3. ALL of the following

    • Possible Lyme arthritis.
    • Use serum antibody testing rather than PCR or culture of blood or synovial fluid/tissue.
    • In a seropositive patient when treatment decisions require more definitive information, PCR of synovial fluid or tissue may be used rather than Borrelia culture.
  4. Collect when the initial result is negative and the lesion is atypical for erythema migrans
    Repeat ELISA after early negative result
    TestELISA
    Initial timingNegative result obtained within 4 weeks of symptom onset
    Repeat intervalRepeat 4 to 6 weeks later
    ConditionLyme disease must remain clinically suspected

    Order a first-tier EIA/ELISA or IFA before confirmatory testing. Do not order an immunoblot as the initial or stand-alone test, because its specificity is reduced without a prior first-tier assay.

    • The initial assay categorizes the result as negative, equivocal, or positive.
    • If negative, no further testing is indicated for that specimen.
    • If positive or equivocal, obtain second-tier testing with a western immunoblot or an FDA-cleared EIA used as a confirmatory test.
    Documentation Required

    Document Clinical and Epidemiologic Support

    Document a clinical illness compatible with Lyme disease together with plausible geographic or epidemiologic exposure before ordering testing. Testing is most appropriate for supported neurologic, cardiac, or musculoskeletal presentations rather than isolated nonspecific findings.

    • Supportive presentations may include meningitis, encephalitis or myelitis, painful radiculoneuritis, mononeuropathy multiplex, acute cranial neuropathy, appropriate myocarditis or pericarditis, or Lyme arthritis.
    • Diffuse arthralgias, myalgias, or fibromyalgia alone do not establish a musculoskeletal Lyme presentation.
    • Avoid testing when clinical or epidemiologic support is absent because false-positive results can lead to inappropriate follow-up and treatment.
    Documentation Required

    Document Testing History and Timing

    Record symptom onset and timing, the specific tests and sequence performed, each result, relevant exposure history, and any prior Lyme treatment. Interpret serology in context: IgM immunoblot testing is useful only during the first 4 weeks after symptom onset, and antibodies may persist for years after treatment.

    • For an atypical EM-like lesion with an initially negative acute-phase result, document the rationale for a convalescent-phase sample collected at least 2–3 weeks later when clinically indicated.
    • Do not use repeat antibody testing to assess treatment success.
    • A prior positive result or prior treatment can complicate interpretation because seroreactivity may persist.
    Denial Risk

    Erythema Migrans: Treat Clinically

    Do not order serologic testing when the clinical presentation is a characteristic erythema migrans rash in a patient with plausible exposure. Diagnose and treat clinically rather than waiting for laboratory confirmation.

    • Patients with a typical EM lesion should be managed on clinical findings.
    • Testing may be considered for lesions suggestive of but atypical for EM, with appropriate acute- and convalescent-phase timing.
    Denial Risk

    Avoid Low-Specificity Testing

    Do not order Lyme serology for asymptomatic screening or for nonspecific symptoms without compatible clinical and epidemiologic support.

    • Examples include fatigue, diffuse myalgias, diffuse arthralgias, or fibromyalgia alone.
    • Asymptomatic serology after a tick bite does not guide treatment decisions.
    Denial Risk

    Avoid Testing for Unsupported Neurologic or Psychiatric Conditions

    Do not routinely order Lyme testing for the listed neurologic or psychiatric conditions when Lyme-specific clinical or epidemiologic support is absent.

    • Amyotrophic lateral sclerosis.
    • Relapsing-remitting multiple sclerosis.
    • Parkinson's disease.
    • Dementia or cognitive decline, new-onset seizures, or psychiatric illness.
    • Other neurologic syndromes or nonspecific brain white-matter abnormalities without additional Lyme support.
    Denial Risk

    Avoid Routine Nucleic Acid Identification

    Do not use direct or amplified-probe nucleic acid identification as a routine covered method for detecting Borrelia burgdorferi. Serum antibody testing is preferred for suspected neuroborreliosis, and PCR or culture of blood or CSF is not routinely recommended.

    • PCR testing of blood is not well established and is generally negative in early and late disease.
    • PCR of synovial fluid or tissue may have a limited role in selected seropositive patients when evaluating possible Lyme arthritis.
    Denial Risk

    Do Not Repeat Serology After a Positive Result

    Do not repeat Lyme serology solely because a patient previously tested positive or to determine whether treatment was successful. Antibodies can remain detectable for years and do not demonstrate persistent infection or treatment failure.

    • A prior positive result should be documented and considered when interpreting any subsequent evaluation.
    • Do not repeat antibody testing as a test-of-cure.
    Denial Risk

    Avoid Unlisted or Unvalidated Testing

    Testing for Borrelia burgdorferi that is not specifically described as covered does not meet coverage criteria. Use standardized, FDA-cleared two-tier serologic methods rather than unvalidated commercial assays or nonstandard antibody panels.

    • Urine tests, CD57 assays, novel culture techniques, and nonstandard antibody panels are not appropriate diagnostic tests.
    • Document the clinical indication and the validated method used.
    Denial Risk

    Do Not Test the Individual Tick for Lyme Disease

    Do not test an individual removed tick for Borrelia burgdorferi to diagnose Lyme disease. Tick testing does not reliably predict whether the exposed individual has a clinical infection or requires treatment.

    • Species identification of a removed tick may be submitted as a separate good-practice action.
    • Do not use a positive or negative tick test as a substitute for evaluating the patient's symptoms, exposure, and clinical risk.
    Denial Risk

    Require Compatible Clinical or Epidemiologic Support

    Do not order Lyme testing when compatible clinical findings and plausible epidemiologic exposure are absent. Testing in low-value scenarios increases false-positive results and may delay evaluation of other diagnoses or lead to unnecessary antibiotic exposure.

    • Avoid screening for unsupported neurologic syndromes, nonspecific MRI white-matter abnormalities, psychiatric or developmental conditions, and nonspecific musculoskeletal symptoms.
    • Evaluate for alternative infectious and noninfectious diagnoses when the presentation is not compatible with Lyme disease.
    Billing Rule

    Follow the Two-Tier Testing Algorithm

    Follow the complete two-tier algorithm: order an initial EIA/ELISA or IFA, then perform appropriate second-tier testing only when the first-tier result is positive or equivocal. A western immunoblot is the standard second tier; an FDA-cleared EIA-based second-tier test is an acceptable modified algorithm.

    • Do not perform second-tier testing after a negative first-tier result unless a clinically appropriate algorithm specifically supports additional evaluation.
    • For suspected neuroborreliosis, use serum antibody testing rather than routine PCR or culture.
    • For suspected Lyme arthritis, use serum antibody testing before considering selected synovial-fluid or tissue PCR.
    Documentation Required

    Use Paired CSF and Serum Samples

    When evaluating suspected central nervous system Lyme neuroborreliosis and performing CSF testing, obtain simultaneous CSF and serum samples for a CSF:serum antibody index using a validated laboratory method.

    • Do not order CSF serology without measurement of the CSF:serum antibody index.
    • Routine PCR or culture of CSF or serum is not recommended.
    EM
    AbbreviationEM
    Full termErythema migrans
    Clinical contextA characteristic Lyme disease skin lesion
    Testing approachTypical EM is diagnosed clinically without laboratory testing
    STTT
    AbbreviationSTTT
    Full termStandardized two-tier testing
    First tierEIA/ELISA or IFA
    Second tierWestern immunoblot when the first-tier result is positive or equivocal
    MTTT
    AbbreviationMTTT
    Full termModified two-tiered testing
    First tierEIA/ELISA or IFA
    Second tierAn FDA-cleared EIA used as the confirmatory test instead of a western immunoblot
    PCR
    AbbreviationPCR
    Full termPolymerase chain reaction
    Policy contextDirect detection method evaluated against serologic testing
    Routine useRoutine blood or CSF PCR is not recommended for typical evaluation
    LNB
    AbbreviationLNB
    Full termLyme neuroborreliosis
    Clinical contextSuspected Lyme disease involving the peripheral or central nervous system
    CSF evaluationUse simultaneous CSF and serum samples for a CSF:serum antibody index when CSF testing is performed
    Two-tier testing
    First tierEIA or IFA
    Second tierWestern immunoblot or another FDA-cleared second-tier EIA
    TriggerPerform the second tier when the first-tier result is positive, equivocal, or indeterminate
    Negative first tierNo further testing of that specimen is indicated
    Modified two-tier testing
    First tierEIA/ELISA or IFA
    Confirmatory testFDA-cleared EIA used as the second-tier test
    PurposeConfirms a positive or equivocal first-tier result
    Alternative toWestern immunoblot in the standard two-tier algorithm
    CSF:serum antibody index
    SamplesSimultaneous CSF and serum samples
    MeasurementCSF-to-serum antibody index
    PurposeEvaluate intrathecal antibody production
    MethodologyTesting should be performed by a laboratory using validated methodology
    Erythema migrans
    TermErythema migrans
    DefinitionA characteristic Lyme disease skin lesion
    Clinical diagnosisMay support diagnosis without laboratory testing when the presentation and exposure are appropriate
    Typical lesionTypical EM should be diagnosed clinically rather than tested

    Endemic travel plus acute compatible presentation

    • Qualifying presentation: Acute myocarditis or pericarditis of unknown cause; meningitis, encephalitis, or myelitis; painful radiculoneuritis; mononeuropathy multiplex, including confluent mononeuropathy multiplex; or acute cranial neuropathy.At least one presentation

    Suspected Lyme Disease With Compatible Findings and Exposure

    Covered when the clinical findings and geographic or epidemiologic exposure support suspected Lyme disease.

    Compatible illness and plausible exposure

    • Compatible clinical finding: Atypical erythema migrans; acute meningitis, painful radiculoneuritis, mononeuropathy multiplex, acute cranial neuropathy, or spinal cord or brain inflammation; acute myocarditis or pericarditis of unknown cause in an appropriate epidemiologic setting; or compatible Lyme arthritis involving intermittent or persistent arthritis in one or a few large joints, especially the knee.

    Suspected CNS Lyme Neuroborreliosis Requiring CSF Testing

    Covered when central nervous system Lyme neuroborreliosis is suspected and CSF evaluation is clinically indicated.

    CNS neuroborreliosis CSF evaluation: The individual has suspected central nervous system Lyme neuroborreliosis for which CSF testing is clinically indicated.

    Obtain simultaneous CSF and serum samples for determination of a CSF:serum antibody index using a laboratory with validated methodology. CSF serology without measurement of the index is not recommended.

    Seropositive Suspected Lyme Arthritis Requiring Additional Information

    Covered when Lyme arthritis is suspected in a seropositive patient and additional diagnostic information is required for treatment decisions.

    Seropositive suspected Lyme arthritis: The individual is seropositive and Lyme arthritis remains under consideration, but treatment decisions require more definitive diagnostic information.

    Use PCR applied to synovial fluid or tissue rather than Borrelia culture of those samples.

    ReasonAntibodies may persist for many years and serologic status does not establish persistent infection or treatment failure
    ELISA
    TestELISA
    Initial negative resultTest performed within 4 weeks of symptom onset
    Repeat interval4 to 6 weeks later
    RequirementRepeat only if Lyme disease remains suspected